Developer docs
API playgroundTry for free, no card

Search company profiles

Marine Polymer Technologies

Full company profile

uuid000idpd

Namestring
Marine Polymer Technologies
Company typeenum
Private
Founded yearint
1992
Descriptiontext

Marine Polymer Technologies, Inc. (MPT) is a privately held U.S. medical device company founded in 1992 and headquartered in Danvers, Massachusetts. Per the firmographic record, the company is focused on the development and delivery of biomaterials, operating with a headcount of 51-100 employees. The firm has been in continuous operation for over three decades, suggesting an established, regulated commercial business rather than an early-stage venture.

The company's core competency is biomaterials science applied to medical device applications, though the specific product portfolio, indications (e.g., hemostasis, wound management, surgical adjuncts), underlying polymer chemistry, and regulatory clearances were not accessible from the supplied sources — the corporate website at marinepolymer.com returned only a verification/loading page, and no news or third-party sources were attached. No product list, patent inventory, customer base, distribution network, or pricing model was available to characterize the business model in detail.

The revenue mechanics, go-to-market motion, and customer segmentation are similarly under-documented in the available data. There is no disclosed revenue, funding history, ownership structure, management roster, or pipeline of strategic actions, and no source-attributable claims about partnerships, M&A, geographic footprint, or capital raises. Investors evaluating MPT should treat this as a data-thin profile and source primary diligence directly from FDA registration records, USPTO patent filings, and the company's own materials before drawing conclusions.

Short descriptiontext

Marine Polymer Technologies is a privately held U.S. medical device company founded in 1992, headquartered in Danvers, Massachusetts, focused on the development and delivery of biomaterials with a 51-100 employee team.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDanvers, United States
HQ citystring
Danvers
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
medical device manufacturing, biomaterials development, polymer biomaterials, hemostatic biomaterials, wound care devices
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Devices
Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Marine Polymer Technologies, Inc. (MPT) is a medical device company that develops and delivers biomaterial-based products. Its core activity is the research, development, and commercialization of proprietary biomaterials intended for use in medical device applications. The company manufactures and supplies these biomaterial products to the healthcare market.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Ethicon, J&J's surgical solutions arm, dominates the operating room with hemostats, sealants, and anti-adhesion products. MPT competes and partners in the same surgical adjacencies (anti-adhesion, hemostasis), and Ethicon is the canonical strategic-acquirer comp for any biomaterials medical device target.

TypeDirect peer
Description

Teleflex acquired Z-Medica, which makes kaolin-based QuikClot hemostatic gauze — a direct functional competitor in hemostasis with stronger distribution and military contracts (e.g., CoTCCC guidelines). Comparability centers on competing hemostatic mechanism approaches for the same clinical and tactical indications MPT targets.

TypeBroad incumbent
Description

Baxter is a global medical device and biopharmaceutical incumbent with a long-running surgical hemostasis franchise (e.g., Floseal, Tisseel). It overlaps with MPT as an adjacent supplier to the same surgical suites and trauma hospitals, and represents the type of strategic acquirer of a niche biomaterials platform.

TypeDirect peer
Description

Tricol is the commercial successor to HemCon, the most direct chitosan-based hemostatic gauze competitor to MPT. Both companies monetize marine-derived (chitosan) polymers as FDA-cleared hemostatic devices for surgical and tactical/military use, with overlapping product mechanics and channel to trauma centers and DoD procurement.

TypeBroad incumbent
Description

Stryker's surgical and wound-care businesses (acquired with Wright Medical, Instratek) buy into biomaterials and biologic adjacencies. Comparable as a broader MedTech incumbent that the same hospital procurement officers and trauma surgeons might evaluate alongside an MPT proposition.

TypeBroad incumbent
Description

BD operates a broad surgical and biosciences portfolio, including hemostatic and wound-care products sold into the same hospital channels MPT serves. BD is a relevant comparable because it acquires niche biomaterials and hemostatic technology assets to extend its surgical platform.

TypeEmerging player
Description

Carmell is a clinical-stage company developing allogeneic platelet-derived and biomaterial-based tissue repair products for orthopedics and wound healing. Comparable as a similarly-sized emerging biomaterials platform focused on indications adjacent to MPT's hemostasis and tissue-support franchise.

TypeBroad incumbent
Description

Medtronic (post-Covidien) is a leading surgical and biologics franchise with active interest in hemostatic and tissue-adjacent products. Comparable as an OEM-style acquirer of biomaterials platforms with overlapping call points in the OR.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Marine Polymer Technologies

Medical Devicesmarinepolymer.com

Marine Polymer Technologies is a privately held U.S. medical device company founded in 1992, headquartered in Danvers, Massachusetts, focused on the development and delivery of biomaterials with a 51-100 employee team.

What Marine Polymer Technologies does

Marine Polymer Technologies, Inc. (MPT) is a privately held U.S. medical device company founded in 1992 and headquartered in Danvers, Massachusetts. Per the firmographic record, the company is focused on the development and delivery of biomaterials, operating with a headcount of 51-100 employees. The firm has been in continuous operation for over three decades, suggesting an established, regulated commercial business rather than an early-stage venture.

The company's core competency is biomaterials science applied to medical device applications, though the specific product portfolio, indications (e.g., hemostasis, wound management, surgical adjuncts), underlying polymer chemistry, and regulatory clearances were not accessible from the supplied sources — the corporate website at marinepolymer.com returned only a verification/loading page, and no news or third-party sources were attached. No product list, patent inventory, customer base, distribution network, or pricing model was available to characterize the business model in detail.

The revenue mechanics, go-to-market motion, and customer segmentation are similarly under-documented in the available data. There is no disclosed revenue, funding history, ownership structure, management roster, or pipeline of strategic actions, and no source-attributable claims about partnerships, M&A, geographic footprint, or capital raises. Investors evaluating MPT should treat this as a data-thin profile and source primary diligence directly from FDA registration records, USPTO patent filings, and the company's own materials before drawing conclusions.

Marine Polymer Technologies firmographics

Firmographics
Name
Marine Polymer Technologies
Website
https://marinepolymer.com
Company type
Private
Founded year
1992
Operating status
Operating
Headcount range
51–100 employees
Short description
Marine Polymer Technologies is a privately held U.S. medical device company founded in 1992, headquartered in Danvers, Massachusetts, focused on the development and delivery of biomaterials with a 51-100 employee team.
Ownership category
akta.pro rank

Where Marine Polymer Technologies is headquartered

Location

Headquarters

HQ city
Danvers
HQ country
United States
HQ region
North America

Markets served

Marine Polymer Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Marine Polymer Technologies product offering

Product offering

Core offering

Marine Polymer Technologies, Inc. (MPT) is a medical device company that develops and delivers biomaterial-based products. Its core activity is the research, development, and commercialization of proprietary biomaterials intended for use in medical device applications. The company manufactures and supplies these biomaterial products to the healthcare market.

Differentiator

Problem solved

Functional benefit

Companies that use Marine Polymer Technologies

Customer profile

Ideal customer profiles1 record

Marine Polymer Technologies technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Marine Polymer Technologies partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

Marine Polymer Technologies competitors and assessment

Company assessment

Broad incumbents

  • Johnson & Johnson (Ethicon): Ethicon, J&J's surgical solutions arm, dominates the operating room with hemostats, sealants, and anti-adhesion products. MPT competes and partners in the same surgical adjacencies (anti-adhesion, hemostasis), and Ethicon is the canonical strategic-acquirer comp for any biomaterials medical device target.
  • Baxter International: Baxter is a global medical device and biopharmaceutical incumbent with a long-running surgical hemostasis franchise (e.g., Floseal, Tisseel). It overlaps with MPT as an adjacent supplier to the same surgical suites and trauma hospitals, and represents the type of strategic acquirer of a niche biomaterials platform.
  • Stryker Corporation: Stryker's surgical and wound-care businesses (acquired with Wright Medical, Instratek) buy into biomaterials and biologic adjacencies. Comparable as a broader MedTech incumbent that the same hospital procurement officers and trauma surgeons might evaluate alongside an MPT proposition.
  • Becton, Dickinson and Company (BD): BD operates a broad surgical and biosciences portfolio, including hemostatic and wound-care products sold into the same hospital channels MPT serves. BD is a relevant comparable because it acquires niche biomaterials and hemostatic technology assets to extend its surgical platform.
  • Medtronic: Medtronic (post-Covidien) is a leading surgical and biologics franchise with active interest in hemostatic and tissue-adjacent products. Comparable as an OEM-style acquirer of biomaterials platforms with overlapping call points in the OR.

Direct peers

  • Teleflex (Z-Medica / QuikClot): Teleflex acquired Z-Medica, which makes kaolin-based QuikClot hemostatic gauze — a direct functional competitor in hemostasis with stronger distribution and military contracts (e.g., CoTCCC guidelines). Comparability centers on competing hemostatic mechanism approaches for the same clinical and tactical indications MPT targets.
  • Tricol Biomedical (HemCon): Tricol is the commercial successor to HemCon, the most direct chitosan-based hemostatic gauze competitor to MPT. Both companies monetize marine-derived (chitosan) polymers as FDA-cleared hemostatic devices for surgical and tactical/military use, with overlapping product mechanics and channel to trauma centers and DoD procurement.

Emerging players

  • Carmell Therapeutics: Carmell is a clinical-stage company developing allogeneic platelet-derived and biomaterial-based tissue repair products for orthopedics and wound healing. Comparable as a similarly-sized emerging biomaterials platform focused on indications adjacent to MPT's hemostasis and tissue-support franchise.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key highlights5 records

Customer concentration

Marine Polymer Technologies social profiles

Digital presence

Marine Polymer Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Marine Polymer Technologies leadership team

Management profile

Number of profiles

Marine Polymer Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Marine Polymer Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marine Polymer Technologies

What does Marine Polymer Technologies do?

Marine Polymer Technologies, Inc. (MPT) is a medical device company that develops and delivers biomaterial-based products. Its core activity is the research, development, and commercialization of proprietary biomaterials intended for use in medical device applications. The company manufactures and supplies these biomaterial products to the healthcare market.

Is Marine Polymer Technologies a public or private company?

Marine Polymer Technologies is a private company. It is classified as unknown and is currently operating.

When was Marine Polymer Technologies founded?

Marine Polymer Technologies was founded in 1992. It employs 51 to 100 people.

Where is Marine Polymer Technologies based?

Marine Polymer Technologies is headquartered in Danvers, United States, in the North America region.

Who are Marine Polymer Technologies's main competitors?

Broad incumbents on record are Johnson & Johnson (Ethicon), Baxter International, Stryker Corporation, Becton, Dickinson and Company (BD) and Medtronic. Direct peers are Teleflex (Z-Medica / QuikClot) and Tricol Biomedical (HemCon). Carmell Therapeutics is listed as an emerging player.

Does Marine Polymer Technologies have an API?

No public API is recorded for Marine Polymer Technologies.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales